title: The interaction of the diltiazem with oral and intravenous cyclosporine in rats.
abstract: This study investigated the effect of diltiazem on the bioavailability of oral and intravenous cyclosporine (CsA) in rats. While control rats received normal saline, experimental groups received 60 or 90 mg/kg diltiazem orally for 3 days. Each group divided into 2 equal groups that received a single oral dose or i.v. injection of CsA. Pharmacokinetic parameters were analyzed by nonparametric analysis of variance. Pretreatment with 60 or 90 mg/kg diltiazem decreased the area under the blood CsA concentration-time curve (AUC) of oral CsA compared to control group (54.5% and 65.5% for AUC(0-24), 57.6% and 62.2% for AUC(0-infinity), respectively, p<0.05). Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05). The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%). Pretreatment with 90 mg/kg but not 60 mg/kg of diltiazem increased the AUC(0-infinity), elimination half-life (t1/2) of intravenous CsA (116.0%, 219.2%, respectively, p<0.05) and decreased the intravenous CsA clearence (CL(i.v.)) (62.9%, p<0.05). Diltiazem decreased the bioavailability of oral CsA, while it increased the bioavailability of intravenous CsA. One must consider this interaction when administering oral or intravenous CsA concomitantly with diltiazem.
authors.affiliation: Department of Pharmacology, Dokuz Eylul University, School of Medicine, Izmir, Turkey.
authors.forename: Sule
authors.initials: S
authors.lastname: Kalkan
authors.forename: Mukaddes
authors.initials: M
authors.lastname: Gumustekin
authors.forename: Oguz
authors.initials: O
authors.lastname: Aygoren
authors.forename: Yesim
authors.initials: Y
authors.lastname: Tuncok
authors.forename: Ayse
authors.initials: A
authors.lastname: Gelal
authors.forename: Hulya
authors.initials: H
authors.lastname: Guven
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D016572:Cyclosporine / Q000493:pharmacokinetics*; D004110:Diltiazem / Q000494:pharmacology*; D004347:Drug Interactions; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008297:Male; D051381:Rats; D017208:Rats, Wistar
chemical_list: D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D004110:Diltiazem